Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mirikizumab by Eli Lilly and Co for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Mirikizumab is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According...
Abemaciclib by Eli Lilly and Co for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Transitional Cell Cancer (Urothelial...
Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...
Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...
Ramucirumab by Eli Lilly and Co for Thymic Carcinoma: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Thymic Carcinoma. According to...
Baricitinib by Eli Lilly and Co for Polymyalgia Rheumatica (PMR): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR). According...
Mazdutide by Eli Lilly and Co for Obesity: Likelihood of Approval
Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData,...
Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...
Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...
LY-3537021 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval
LY-3537021 is under clinical development by Eli Lilly and Co and currently in Phase I for Type 2 Diabetes. According...
Crenigacestat by Eli Lilly and Co for Natural Killer Cell Lymphomas: Likelihood of Approval
Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase I for Natural Killer Cell Lymphomas....
Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval
Alimta is under clinical development by Eli Lilly and Co and currently in Phase I for Chordoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Peresolimab?
Peresolimab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Autoimmune Disorders....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Mevidalen Hydroxybenzoate?
Mevidalen Hydroxybenzoate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Lewy...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-001?
PR-001 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Parkinson's Disease....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Muvalaplin?
Muvalaplin is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Atherosclerosis. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Imlunestrant tosylate?
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Solbinsiran Sodium?
Solbinsiran Sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase II program in...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Remternetug?
Remternetug is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase III program in Alzheimer's Disease....
Eli Lilly and Co files patent for ret kinase inhibitors
Eli Lilly and Co. has filed a patent for RET kinase inhibitors, which are compounds used in the treatment of...